The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro
Abstract
The atypical antipsychotic olanzapine has relatively high affinity for a number of neuronal receptors in radioreceptor binding assays. The ability of olanzapine to activate or antagonize a number of neuronal receptors was investigated in vitro, in cell lines transfected selectively with receptor subtypes and in receptor-selective isolated tissue studies. Olanzapine had no agonist activity at any of the receptors examined. However, olanzapine was a potent antagonist of 5-HT-stimulated increases in IP3 in cell lines transfected with 5-HT2A or 5-HT2B receptors with IC50 values of 30-40 nM. Olanzapine weakly blocked 5-HT-induced formation of IP3 in cell lines transfected with 5-HT2c receptors, but in this cell line potently inhibited 5-HT-stimulated [35S]GTP gamma S binding with a Ki value of 15 nM. Olanzapine blocked dopamine-stimulated adenylyl cyclase in rat retina with modest potency (Ki = 69 nM), consistent with its relatively low affinity for dopamine D1 receptors. Olanzapine blocked agonist-induced activities at the muscarinic receptor subtypes M1, M2, M3, and M5 with Ki values of 70, 622, 126, and 82 nM, respectively. In studies using cell lines transfected with muscarinic M4 receptors, olanzapine and the atypical antipsychotic clozapine did not have agonist activities as determined with cAMP inhibition and stimulation assays, arachidonic acid release and [35S]GTP gamma S binding assays. However, olanzapine antagonized agonist-induced effects in muscarinic M4 cells with a Ki value of 350 nM. In isolated tissue studies, olanzapine potently blocked agonist-induced effects at alpha 1-adrenergic and histamine H1 receptors (KB = 9 and 19 nM, respectively). Thus, olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5-HT2B, 5-HT2C, alpha 1-adrenergic and histamine H1 receptors. Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“probably due to their strong binding to histamine receptors(Bymaster et al., 1999)”
From Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis (2024) · cites this paper as Bymaster et al., 1999
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
DeLÉAN, A., Munson, P. J., & Rodbard, D. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.235.2.e97 · Cited by 2,384
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Self-citationOpposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum
Stoof, J. C., & Kebabian, J. W. (1981) · Nature · doi:10.1038/294366a0 · Cited by 920
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes
Peralta, E. G., Ashkenazi, A., Winslow, J. W., Ramachandran, J., & Capon, D. J. (1988) · Nature · doi:10.1038/334434a0 · Cited by 658
Sawaguchi, T., & Goldman‐Rakic, P. S. (1994) · Journal of Neurophysiology · doi:10.1152/jn.1994.71.2.515 · Cited by 649
Cited by
Sorted by citations
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 585
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 298
Self-citationAntipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261
Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248
Crook, J. M., Tomaskovic‐Crook, E., Copolov, D., & Dean, B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00918-5 · Cited by 228
Crook, J., Tomaskovic-Crook, E., Copolov, D., & Dean, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.918 · Cited by 224
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 225
Self-citationBhana, N., Foster, R. H., Olney, R., & Plosker, G. L. (2001) · Drugs · doi:10.2165/00003495-200161010-00011 · Cited by 217
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 204
Konradi, C. L., & Heckers, S. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01267-7 · Cited by 201
Jordan, K., Gralla, R., Jahn, F., & Molassiotis, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.073 · Cited by 196
Atypical Antipsychotic-Induced Weight Gain
Roerig, J. L., Steffen, K. J., & Mitchell, J. E. (2011) · CNS Drugs · doi:10.2165/11596300-000000000-00000 · Cited by 168
Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D., & Kollack‐Walker, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000161501.65890.22 · Cited by 164
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C
Lord, C. C., Wyler, S. C., Wan, R., Castorena, C. M., Ahmed, N. I., Mathew, D., Lee, S., Liu, C., & Elmquist, J. K. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93362 · Cited by 161
Atypical antipsychotics in bipolar depression: potential mechanisms of action.
Yatham, L. N., Goldstein, J. M., Vieta, E., Bowden, C. L., Grunze, H., Post, R. M., Suppes, T. M., & Calabrese, J. R. (2005) · PubMed · Cited by 159
Coccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 147
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
Feyer, P., & Jordan, K. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq600 · Cited by 145
Muscarinic mechanisms of antipsychotic atypicality
Bymaster, F. P., Felder, C. C., Tzavara, E. T., Nomikos, G. G., Calligaro, D. O., & McKinzie, D. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.008 · Cited by 140
Self-citationAn update of safety of clinically used atypical antipsychotics
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201475 · Cited by 135
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
Siuciak, J., Chapin, D., McCarthy, S. A., Guanowsky, V., Brown, J. A., Chiang, P., Marala, R., Patterson, T., Seymour, P., Swick, A., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.024 · Cited by 132
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., & Gobbi, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f8770 · Cited by 132
Sowell, M. O., Mukhopadhyay, N. D., Cavazzoni, P. A., Shankar, S. S., Steinberg, H. O., Breier, A. F., Beasley, C. M., & Dananberg, J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8599 · Cited by 129
Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine
Bymaster, F. P., Falcone, J. F., Bauzon, D., Kennedy, J. S., Schenck, K. W., DeLapp, N. W., & Cohen, M. L. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01399-1 · Cited by 122
Self-citationThe Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., Pavlovic, Z. M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 121
An animal model of antipsychotic-induced weight gain
Arjona, A. A. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.040 · Cited by 118
The Role of Thermogenesis in Antipsychotic Drug‐induced Weight Gain
Stefanidis, A., Verty, A. N. A., Allen, A. M., Owens, N. C., Cowley, M. A., & Oldfield, B. J. (2008) · Obesity · doi:10.1038/oby.2008.468 · Cited by 105
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats
Weston–Green, K., Huang, X., & Deng, C. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.039 · Cited by 105
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
Bisson, W. H., Cheltsov, A. V., Bruey-Sédano, N., Lin, B., Chen, J., Goldberger, N. E., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609752104 · Cited by 99
Alterations of Serotonin Transmission in Schizophrenia
Abi‐Dargham, A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78005-9 · Cited by 98
In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390
Ekelund, J., Slifstein, M., Narendran, R., Guillin, O., Belani, H., Guo, N., Hwang, Y., Hwang, D., Abi‐Dargham, A., & Laruelle, M. A. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0077-4 · Cited by 95
Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors
Bock, J. R., & Gough, D. A. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci050006d · Cited by 99
Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance
Martins, P. J. F., Haas, M., & Obici, S. (2010) · Diabetes · doi:10.2337/db10-0449 · Cited by 97
In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia
Raedler, T. J. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00162-1 · Cited by 82
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., & Gil‐Ad, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0731-1 · Cited by 80
Jutila, A., Söderlund, T., Pakkanen, A. L., HUTTUNEN, M. O., & Kinnunen, P. K. J. (2001) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(01)00175-x · Cited by 80
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine
Mann, K., Rossbach, W., Müller, M. J., Müller-Siecheneder, F., Pott, T., Linde, I., Dittmann, R. W., & Hiemke, C. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.08.005 · Cited by 78
Bymaster, F. P., & Felder, C. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001019 · Cited by 76
Self-citationYanai, T., Iwasa, S., Hashimoto, H., Ohyanagi, F., Takiguchi, T., Takeda, K., Nakao, M., Sakai, H., Nakayama, T., Minato, K., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1200-4 · Cited by 74
An open pilot trial of olanzapine for delirium in the Korean population
Kim, K., Pae, C., Chae, J., Bahk, W., & Jun, T. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00898.x · Cited by 75
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Weizman, R., & Weizman, A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2935-2 · Cited by 74
de Bartolomeis, A., Barone, A., Begni, V., & Riva, M. A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106078 · Cited by 79
Minet-Ringuet, J., Even, P., Goubern, M., Tomé, D., & de Beaurepaire, R. (2006) · Appetite · doi:10.1016/j.appet.2006.01.008 · Cited by 74
Olanzapine in the Treatment of Developmental Stuttering: A Double-Blind, Placebo-Controlled Trial
Maguire, G. A., Riley, G. D., Franklin, D. L., Maguire, M. E., Nguyen, C. T., & Brojeni, P. H. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490452834 · Cited by 69
Davoodi, N., Kalinichev, M., Korneev, S. A., & Clifton, P. G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1415-1 · Cited by 67
Carli, M., Calcagno, E., Mainolfi, P., Mainini, E., & Invernizzi, R. W. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2065-7 · Cited by 65
Comparison of Olanzapine to Risperidone in Substance‐Abusing Individuals with Schizophrenia
Akerele, E., & LEVIN, F. R. (2007) · American Journal on Addictions · doi:10.1080/10550490701389658 · Cited by 63
Bhana, N., & Perry, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115110-00005 · Cited by 62
Chemogenomics in Drug Discovery
Kubinyi, H. (2007) · Springer eBooks · doi:10.1007/978-3-540-37635-4_1 · Cited by 62
Bortolozzi, A. A., Amargós‐Bosch, M., Adell, A., Díaz-Mataix, L., Serrats, J., Pons, S., & Artigas, F. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02829.x · Cited by 62
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 58
Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder
Keshavan, M. S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.12.008 · Cited by 57
Brea, J. M., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M. I., Enguix, M. J., Villazón, M., Mengod, G., Caro, Y., Masaguer, C. F., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm011014y · Cited by 56
The Benefits of Olanzapine in Palliating Symptoms
Davis, M. P., & Sanger, G. J. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00804-1 · Cited by 54
Effect of a single-dose of olanzapine on sleep in healthy females and males
Lindberg, N., Virkkunen, M., Tani, P., Appelberg, B., Virkkala, J., n, R. R., & Porkka‐Heiskanen, T. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200207000-00004 · Cited by 54
Teaktong, T., Piggott, M. A., McKeith, I. G., Perry, R. H., Ballard, C. G., & Perry, E. K. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.019 · Cited by 53
Receptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 52
Perry, K. W., Nisenbaum, L. K., George, C. A., Shannon, H. E., Felder, C. C., & Bymaster, F. P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01017-9 · Cited by 52
Self-citationActivity-based anorexia animal model: a review of the main neurobiological findings
Spadini, S., Ferro, M., Lamanna, J., & Malgaroli, A. (2021) · Journal of Eating Disorders · doi:10.1186/s40337-021-00481-x · Cited by 56
Serotonergic approaches in the development of novel antipsychotics
Jones, C. A., & McCreary, A. C. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.025 · Cited by 50
Dalton, G. L., Lee, M. D., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.012 · Cited by 50
Didriksen, M., Kreilgaard, M., & Arnt, J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.021 · Cited by 50
Ichikawa, J., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02544-1 · Cited by 49
Upright, N. A., & Baxter, M. G. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0660-9 · Cited by 45
Jin, C. Y., & Panula, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.017 · Cited by 47
Cognitive effects of olanzapine treatment in schizophrenia.
McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004) · PubMed Central · Cited by 47
Coccurello, R., Caprioli, A., Ghirardi, O., Conti, R., Ciani, B., Daniele, S., Bartolomucci, A., & Moles, A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0368-5 · Cited by 47
Torta, R., & Monaco, F. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2008.x · Cited by 45
Coccurello, R., Brina, D., Caprioli, A., Conti, R., Ghirardi, O., Schepis, F., & Moles, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bfe13e · Cited by 44
Bymaster, F. P., & Falcone, J. F. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00037-6 · Cited by 44
Self-citationWang, D., Schneider-Thoma, J., Siafis, S., Qin, M., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.03.003 · Cited by 44
Wiśniewska, A., & Wolnicka-Głubisz, A. (2004) · Biophysical Chemistry · doi:10.1016/j.bpc.2004.04.001 · Cited by 42
van der Zwaal, E. M., Merkestein, M., Lam, Y. K., Brans, M. A. D., Luijendijk, M. C. M., Bok, L. I. H., Verheij, E. R., la Fleur, S. E., & Adan, R. A. H. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.97 · Cited by 39
Rodygin, K. S., Bogachenkov, A. S., & Ananikov, V. P. (2018) · Molecules · doi:10.3390/molecules23030648 · Cited by 39
Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents
Calarge, C. A., Ivins, S. D., Motyl, K. J., Shibli-Rahhal, A. A., Bliziotes, M. M., & Schlechte, J. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313487548 · Cited by 39
Sato, H., Ito, C., Hiraoka, K., Tashiro, M., Shibuya, K., Funaki, Y., Yoshikawa, T., Iwata, R., Matsuoka, H., & Yanai, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4002-2 · Cited by 40
Freedenfeld, R. N., Murray, M., Fuchs, P. N., & Kiser, R. S. (2006) · Pain Practice · doi:10.1111/j.1533-2500.2006.00072.x · Cited by 38
Deng, C., Weston–Green, K., Han, M., & Huang, X. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.02.009 · Cited by 35
Antipsychotics as antidepressants
Roberts, R. J., Lohano, K., & El‐Mallakh, R. S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12186 · Cited by 35
Bai, Y. M., Chen, T., Liou, Y., Hong, C., & Tsai, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.030 · Cited by 33
Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats
Li, M., Budin, R., Fleming, A. S., & Kapur, S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.012 · Cited by 34
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine
Rico‐Villademoros, F., Hidalgo, J. L. L., Dominguez, I., Garcia‐Leiva, J. M., & Calandre, E. P. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.08.012 · Cited by 33
Liu, C., Lee, S., & Elmquist, J. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.02.008 · Cited by 33
Treatment of Intractable Hiccups With Olanzapine Following Recent Severe Traumatic Brain Injury
Alderfer, B. S., & Arciniegas, D. B. (2006) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.18.4.551 · Cited by 32
Cognitive impairment in elderly patients with schizophrenia: age related changes
Harvey, P. D. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200112)16:1+ · Cited by 44
Self-citationAntipsychotics as antidepressants: what is the mechanism?
Šagud, M., Mihaljević-Peleš, A., Begić, D., Vuksan‐Ćusa, B., Kramarić, M., Živković, M., & Jakovljević, M. (2011) · PubMed · Cited by 29
Raedler, T. J. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006584 · Cited by 29
Evers, S. S., Calcagnoli, F., van Dijk, G., & Scheurink, A. J. W. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.029 · Cited by 28
From ultimatum to Nash bargaining: Theory and experimental evidence
Fischer, S., Güth, W., Müller, W., & Stiehler, A. (2006) · Experimental Economics · doi:10.1007/s10683-006-1468-0 · Cited by 28
Muscarinic mechanisms in psychotic disorders.
McKinzie, D., & Bymaster, F. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_9 · Cited by 22
Self-citationVanover, K. E., Harvey, S. C., Son, T., Bradley, S. R., Kold, H., Makhay, M. M., Veinbergs, I., Spalding, T. A., Weiner, D. M., Andersson, C., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.066688 · Cited by 27
Oruch, R., Lund, A., Pryme, I. F., & Holmsen, H. (2010) · Journal of Chemical Biology · doi:10.1007/s12154-009-0034-6 · Cited by 26
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Gyawali, B., Poudyal, B. S., & Iddawela, M. Y. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2015.002477 · Cited by 26
Complexity, Bounded Rationality and Heuristic Search
MacLeod, W. B. (2001) · Contributions in Economic Analysis & Policy · doi:10.2202/1538-0645.1059 · Cited by 26
Nallapati, S. B., Sreenivas, B. Y., Bankala, R., Parsa, K. V. L., Shivashankar, S., Mukkanti, K., & Pal, M. (2015) · RSC Advances · doi:10.1039/c5ra20380e · Cited by 25
Choy, K. H. C., Shackleford, D. M., Malone, D. T., Mistry, S. N., Patil, R. T., Scammells, P. J., Langmead, C. J., Pantelis, C., Sexton, P. M., Lane, J. R., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235788 · Cited by 25
Asaoka, N., Nagayasu, K., Nishitani, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.032 · Cited by 25
123I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M1In Vivo
Bakker, G., Vingerhoets, W. A. M., van Wieringen, J., de Bruin, K. M., Eersels, J. L. H., de Jong, J., Chahid, Y., Rutten, B. P. F., DuBois, S. L., Watson, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147488 · Cited by 24
Zhao, C., & Li, M. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.021 · Cited by 24
Optimization of a mathematical topological pattern for the prediction of antihistaminic activity
Duart, M. J., García‐Domenech, R., Antón-Fos, G. M., & Gálvez, J. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1011115824070 · Cited by 23
Metadata
- Authors
- Bymaster, F.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Bymaster, F
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 1999-05-04
- Volume
- 37
- Issue
- 1
- Pages
- 107-122
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2113107587
- Cited by
- 200
- References
- 62
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 10 · 2014: 5 · 2013: 5 · 2012: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- olanzapine, atypical antipsychotics
- MeSH terms
- Olanzapine, Adenylyl Cyclases, Animals, Benzodiazepines, Cells, Cultured, Cricetinae, Kinetics, Pirenzepine, Receptors, Adrenergic, alpha, Receptors, Histamine H1, Receptors, Muscarinic, Receptors, Serotonin, Retina, Receptors, Dopamine D1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
